Impact of clinical pharmacist on cost of drug therapy in the ICU  by Aljbouri, Tareq M. et al.
Saudi Pharmaceutical Journal (2013) 21, 371–374King Saud University
Saudi Pharmaceutical Journal
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEImpact of clinical pharmacist on cost of drug
therapy in the ICU* Corresponding author.
E-mail address: tareq.baghdadi@gmail.com (T.M. Aljbouri).
Peer review under responsibility of King Saud University.
Production and hosting by Elsevier
1319-0164 ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.jsps.2012.12.004Tareq M. Aljbouri a,*, Mohammed S. Alkhawaldeh a
Ala’a eddeen K. Abu-Rumman a, Thamer A. Hasan b
Hakeem M. Khattar c, Atallah S. Abu-Oliem da Pharmaceutical Services and Medicines Control, University of Bradford, UK
b Pharmacy, University of Baghdad, Iraq
c Pharmacy, Jordan University of Science & Technology, Jordan
d Clinical Pharmacy, University of Jordan, JordanReceived 10 September 2012; accepted 6 December 2012
Available online 21 December 2012KEYWORDS
Clinical pharmacist;
Intensive care unit;
Drugs consumption;
Cost savingAbstract Objective: To determine whether the presence of Clinical Pharmacist affects the cost of
drug therapy for patients admitted to the Intensive Care Unit (ICU) at Al-Hussein hospital at
Royal Medical Services in Amman, Jordan.
Method: This study compares the consumed quantities of drugs over two periods of time. Each
period was ten months long. In the second period there was a Clinical Pharmacist. The decrease in
consumption rate of drugs is considered to be an indicator of the success of Clinical Pharmacist in
the ICU, as any decrease in consumption rate reﬂects the correct application of Clinical Pharmacy
practices. The cost of this decrease in consumption rate represents the total reduction of drug ther-
apy cost.
Results: The total reduction of drug therapy cost after applying Clinical Pharmacy practices in
the ICU over a period of ten months was 149946.80 JD (211574.90 USD), which represents an aver-
age saving of 35.8% when compared to the ﬁrst period in this study.
Conclusion: The results of this study showed a signiﬁcant reduction in the consumed quantities
of drugs and therefore a reduction in cost of drug therapy. Such ﬁndings highlight the importance of
the presence of Clinical Pharmacist in all Jordanian hospitals wards and units.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
As the preparation and manufacturing of drugs moved from
pharmacists to the pharmaceutical manufacturing industry,
and dispensing practices became functions that could be well
done by new technology machines or by pharmacy technicians,
the pharmacists role of counting and pouring has changed
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volume of medications and therapy options increased the com-
plexity of information in areas such as pharmaceutical formu-
lation, drug related problems, rational drug use, dosage forms,
pharmacodynamics, adverse effects, drug interactions, patient
adherence to treatment, and pharmacoeconomics. To all these
changes the pharmacists have responded in a positive way. In
addition the physicians’ expertise may not be in these extended
subjects as it is in patient diagnosis and disease treatment.
Nurses also face difﬁculties as they do not have extra time
and enough theoretical and practical background to comply
with these developments (Parthasarathi et al., 2004).
Clinical pharmacy has been deﬁned by the American Col-
lege of Clinical Pharmacy (ACCP), as ‘‘a health science disci-
pline in which pharmacists provide patient care that
optimizes medication therapy and promotes health, wellness,
and disease prevention’’ (ACCP, 2012). It can be concluded
that clinical pharmacy needs different professional work and
skills toward the patient which can be optimized by encourag-
ing more cooperation between pharmacists and other health
care staff to reach desired outcomes. For clinical pharmacist,
it is necessary to know and decide the goal of therapy, best
drug choice, choosing between drug alternatives, risks and risk
– beneﬁt ratio, knowledge of adverse drug events (ADE) and
drug interactions. In addition, clinical pharmacists should be
well aware on how to use the drug (Buch, 2010).
The main aim of this work is to determine the effect of the
presence of a Clinical Pharmacist on the cost of drug therapy
in Intensive Care Unit (ICU).
2. Method
This study was carried out at Al-Hussein hospital at Royal
Medical Services (RMS) in Amman, Jordan. It is considered
to be a comparative study between the consumed quantities
of two different groups of drugs: Anti-infective and Cardiovas-
cular drugs, which are considered the most frequently used in
ICU. Parenteral dosage form was selected because it is used for
the majority of patients and it is the most expensive dosage
form. The data were collected from the ICU pharmacy records
covering two periods:Table 1 Consumption of Anti-infective drugs in the two periods.
No. Drug Consumption
in 1st period
1 Imipenem & cilastatin 4735
2 Benzyl penicillin 528
3 Metronidazole 3958
4 Vancomycin 3476
5 Fluconazole 690
6 Acyclovir 531
7 Amikacin 2500
8 Ceftazidime 3607
9 Gentamicin 1472
10 Cefepime 1211
11 Tazobactam 4502
12 Cefotaxime 2907
13 Ciproﬂoxacillin 334
14 Ceftriaxone 5186
15 Azithromycin 151
16 Flucloxacillin 38041st period: from August 2009 until May 2010, where no
Clinical Pharmacist was present in the ICU.
2nd period: from June 2010 until March 2011, where a Clin-
ical Pharmacist was present in the ICU.
The average purchasing price of each drug was elicited from
RMS orders and tenders in 2009 and 2010. The total cost of
each drug was calculated by multiplying the average purchas-
ing price with the total consumed quantities of that drug. The
sum of all drugs’ total cost in each group represents the total
cost of that group. The difference in the total cost of each
group between the two periods, i.e. saving was calculated.
The sum of savings of both groups represents the total reduc-
tion of drug therapy.
3. Results
3.1. Drugs consumption changes
The consumed quantities in the absence (1st period) and pres-
ence (2nd period) of Clinical Pharmacist, the difference in con-
sumption between the two periods and the reduction
percentage for the studied drug groups are shown in details
below.
3.1.1. Anti-infective drugs
Table 1 shows the total consumed quantities for the most fre-
quently used Anti-infective drugs in presence and absence of
Clinical Pharmacist. It also shows the change in consumed
quantities and the percentage of these changes which ranged
between 23.3% and 79.6%. The highest reduction percentage
was ranked by Flucloxacillin; the average for the reduction
percentage was 44.7%. All values were found to be signiﬁ-
cantly different (P 6 0.01).
3.1.2. Cardiovascular drugs
The most frequently used drug in this group was Furose-
mide while the least commonly used was Nimodipine as
shown in Table 2. The highest value for reduction percent-
age was for Hydralazine (70.7%), and the lowest was for
Furosemide (8%), the average for reduction percentageConsumption
in 2nd period
Diﬀerence in
consumption
Reduction
percentage (%)
3633 1102 23.3
360 168 31.8
2677 1281 32.4
2268 1208 34.8
349 341 49.4
339 192 36.2
1586 914 36.6
2230 1377 38.2
874 598 40.6
692 519 42.9
2370 2132 47.4
1409 1498 51.5
157 177 53.0
2385 2801 54.0
54 97 64.2
775 3029 79.6
Table 2 Consumption of Cardiovascular drugs in the two periods.
No. Drug Consumption in
1st period
Consumption in
2nd period
Diﬀerence in
consumption
Reduction
percentage (%)
1 Furosemide 13599 12487 1112 8.2
2 Nitroglycerin 5380 4600 780 14.5
3 Adrenaline 5855 4520 1335 22.8
4 Dopamine 5962 4360 1602 26.9
5 Alprostadil 587 426 161 27.4
6 Labetalol 951 680 271 28.5
7 Heparin 1575 1037 538 34.2
8 Dobutamine 188 113 75 39.9
9 Nimodipine 88 50 38 43.2
10 Nor-adrenaline 1946 650 1296 66.6
11 Tinzaparin 969 317 652 67.3
12 Hydralazine 605 177 428 70.7
Table 3 Total cost difference in the two periods.
Drug group Total cost of 1st period (JD*) Total cost of 2nd period (JD*) Diﬀerence i.e. saving (JD*) Diﬀerence (%)
Anti-infectives 324060.40 189150.20 134910.20 41.6
Cardiovascular 50122.42 35085.83 15036.59 30.0
* JD: Jordanian Dinars, 1JD = 1.411 USD (conversion rate valid August 2011).
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ent (P 6 0.01).
3.2. Change in the cost
The total cost of each group was calculated depending on the
total consumed quantity and the average purchasing price of
each drug.
The difference i.e. saving in the total cost of consumed
drugs between the 1st period and 2nd period is clearly evident
as shown in Table 3. The total reduction of drug therapy cost
after applying Clinical Pharmacy practices in ICU was
149946.79 JD (211574.92 USD) which represent an average
saving of 35.8% against the cost of the 1st period in the study.
4. Discussion
ICU patients are critically ill patients and their treatment is
challenging as they usually have more than one condition, al-
tered organ functions and require many drugs. These patients
require ‘polypharmacy’ to help in their condition. However the
use of drug combinations brings risks as these combinations
may contribute to ADE, complications, and drug interactions.
In such an environment, the presence of a Clinical Pharmacist
with thorough knowledge of clinical management of ADE,
pharmacokinetics, pharmacodynamics, drug–drug and drug–
food interactions could promote the rational use of drugs,
and thus reduce the cost of drug therapy. The studies which
were carried out in this ﬁeld suggest that savings can be sub-
stantial (Maclaren et al., 2006). Seventeen years ago the ACCP
estimated that a beneﬁt of 16.70 USD is realized for every
1.00 USD invested in Clinical Pharmacy programs (Saokaew
et al., 2009).
This study has also demonstrated the cost effectiveness for
the presence of a Clinical Pharmacist in the ICU of a majorhospital in Jordan. The study shows that applying Clinical
Pharmacy practices results in a signiﬁcant decrease of selected
drugs consumption as shown in Tables 1 and 2. It must be
stressed out that there were no changes in the study parameters
during the two periods except the presence of Clinical Pharma-
cist. It can be concluded that the reduction in consumption is
due to accurate application of Clinical Pharmacy practices,
which include patient data collection and evaluation, correct
documentation, identifying and solving drug related problems
and reactive clinical interventions.
The reactive interventions that were carried by a Clinical
Pharmacist and brought about such changes may have been;
changing the drug administration route, discontinuing unnec-
essary drug, for example duplicate therapy or unnecessary
antibiotics combinations, change dosing time, recommending
another cheaper therapy and monitoring treatment parame-
ters, teaching the nursing staff to decrease drug waste and de-
crease medication errors.
The decrease in cost is correlated with a reduced consump-
tion rate. This leads to decrease in the total cost of drug ther-
apy for ICU patients as shown in Table 3. A Clinical
Pharmacist could reduce the total cost of treatment indirectly
by decreasing the annually purchased quantity of drugs, stor-
age and delivery of these drugs.
These cost savings show that the presence of Clinical Phar-
macists in an integrated health care system is both important
ﬁnancially as well as clinically. A greater overall reduction in
the cost of drug therapy could be achieved if results were
extrapolated to the hospital setting as a whole or if the data
were collected for all drugs that are used in ICU.5. Conclusion
Applying Clinical Pharmacy practices in ICU proved to reduce
the cost of drug therapy in addition to improving the quality of
374 T.M. Aljbouri et al.health care provided to patients. When such practices are ap-
plied to the whole hospital system it may lead to better health
care services provided to patients as well as reducing the drug
budget, both of which would be beneﬁcial for the RMS and
other health care systems.
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